Evolent Health, Inc.
EVH · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.25 | 0.54 | -0.03 | 0.00 |
| FCF Yield | 0.71% | -3.00% | -0.37% | -2.50% |
| EV / EBITDA | 132.86 | 157.16 | -59.77 | 143.27 |
| Quality | ||||
| ROIC | 0.04% | -0.05% | -0.08% | -0.87% |
| Gross Margin | 20.81% | 22.59% | 21.19% | 11.71% |
| Cash Conversion Ratio | -0.76 | 0.59 | -0.07 | 1.15 |
| Growth | ||||
| Revenue 3-Year CAGR | 4.69% | 10.40% | 17.39% | 23.63% |
| Free Cash Flow Growth | 117.52% | -870.32% | 87.55% | -361.55% |
| Safety | ||||
| Net Debt / EBITDA | 66.45 | 54.98 | -21.72 | 45.87 |
| Interest Coverage | 0.05 | -0.10 | -0.16 | -2.77 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 55.45 | 54.49 | 66.46 | 42.58 |